Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
| Descriptor ID |
D000972
|
| MeSH Number(s) |
D27.505.954.248.179
|
| Concept/Terms |
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in this website by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 4 | 1 | 5 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 1 | 4 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 2 | 4 |
| 2007 | 4 | 0 | 4 |
| 2008 | 3 | 1 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 2 | 5 |
| 2012 | 4 | 1 | 5 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 4 | 6 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased a-Catenin. Prostate. 2025 Feb; 85(2):156-164.
-
Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. Cancer. 2025 Jan 01; 131(1):e35566.
-
Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea. Food Chem Toxicol. 2022 Aug; 166:113246.
-
Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation. Chem Biol Interact. 2022 Jun 01; 360:109946.
-
Recent advances of cannabidiol studies in medicinal chemistry, pharmacology and therapeutics. Future Med Chem. 2021 11; 13(22):1935-1937.
-
Impact of drug formulations on kinetics and toxicity in a preclinical model of paclitaxel-induced neuropathy. J Peripher Nerv Syst. 2021 Jun; 26(2):216-226.
-
Usefulness of the measurement of neurite outgrowth of primary sensory neurons to study cancer-related painful complications. Biochem Pharmacol. 2021 06; 188:114520.
-
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021 12; 70(12):2238-2248.
-
Chemotherapy-induced peripheral neuropathy in a dish: dorsal root ganglion cells treated in vitro with paclitaxel show biochemical and physiological responses parallel to that seen in vivo. Pain. 2021 01; 162(1):84-96.
-
Neither iatrogenic nor hereditary cause: A rare case of anaphylaxis to low sorb tubing used for infusions. Pediatr Blood Cancer. 2021 04; 68(4):e28800.